ArticleJournal of cardiac failure2011
Doxercalciferol, a pro-hormone of vitamin D, prevents the development of cardiac hypertrophy in rats.
Article in Journal of cardiac failure, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 26 citations in OpenAlex.
- Understanding the Role of Vitamin D in Heart Failure.Reviews in cardiovascular medicine · 2023Review
- Inhibition of GTPase Rac1 expression by vitamin D mitigates pressure overload-induced cardiac hypertrophy.International journal of cardiology. Heart & vasculature · 2021Article
- Vitamin D and Atherosclerotic Cardiovascular Disease.The Journal of clinical endocrinology and metabolism · 2019Article
- Vitamin D Receptor Deficiency Does Not Affect Blood Pressure and Heart Function.Frontiers in physiology · 2019Article
- Vitamin D and Calcimimetics in Cardiovascular Disease.Seminars in nephrology · 2018Review
- Article
- The Effects of Vitamin D Supplementation on Signaling Pathway of Inflammation and Oxidative Stress in Diabetic Hemodialysis: A Randomized, Double-Blind, Placebo-Controlled Trial.Frontiers in pharmacology · 2018Article
- Vitamin D and its effects on cardiovascular diseases: a comprehensive review.The Korean journal of internal medicine · 2016Review
- Extraskeletal actions of vitamin D.Annals of the New York Academy of Sciences · 2016Review
- Vitamin D depletion aggravates hypertension and target-organ damage.Journal of the American Heart Association · 2015Article
- What have we learned about chronic kidney disease-mineral bone disorder from the EVOLVE and PRIMO trials?Current opinion in nephrology and hypertension · 2013Review
- Vitamin D and the heart.American journal of physiology. Regulatory, integrative and comparative physiology · 2013Review
- Vitamin D signaling pathway plays an important role in the development of heart failure after myocardial infarction.Journal of applied physiology (Bethesda, Md. : 1985) · 2013Article
- The Vitamin D Analogs Doxercalciferol Induces Weight Loss and Improves Fertility in a Mouse Model of Polycystic Ovary Syndrome.Reproductive medicine and biologyArticle
- Relationship Between 25-Hydroxyvitamin D, Renin, and Collagen Remodeling Biomarkers in Atrial Fibrillation.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundActivated vitamin D analog, paricalcitol, has been shown to attenuate the development of cardiac hypertrophy in Dahl salt sensitive (DSS) rats. To determine whether an antihypertrophic effect is class specific, we tested if doxercalciferol (a pro-hormone vitamin D2 analog) could also attenuate the development of cardiac hypertrophy in DSS rats. METHODS AND
resultsMale DSS rats were fed a high salt (HS) diet for 6 weeks beginning at 6 weeks of age. Doxercalciferol was administered intraperitoneally at 150 ng, 3 times per week (Monday, Wednesday, Friday) for 6 weeks. Pathological and echocardiographic findings demonstrated that rats on HS diet with doxercalciferol administration had significant decrease in cardiac hypertrophy and improved cardiac function compared to the HS + vehicle. In addition, there was a significant decrease in plasma brain natriuretic peptide (BNP) level and tissue atrial natriuretic factor (ANF) mRNA level with doxercalciferol treatment. Doxercalciferol also significantly reduced the level of protein kinase C-α (PKCα) suggesting that PKC-mediated cardiac hypertrophy may be associated with vitamin D deficiency.
conclusionsAdministration of doxercalciferol attenuated the development of HS diet induced cardiac hypertrophy and cardiac dysfunction in DSS rats.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.